Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis

An aerosol form of aztreonam lysinate has recently been developed as a treatment for cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa lung colonization. Local administration means the drug can reach mucus concentrations in the order of hundreds of times the MIC 50 of Pseudomona...

Full description

Saved in:

Bibliographic Details
Published in:	Expert review of anti-infective therapy Vol. 9; no. 11; pp. 967 - 973
Main Author:	Assael, Baroukh Maurice
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis 01.11.2011 Expert Reviews Ltd Informa Healthcare
Subjects:	Administration, Inhalation Adolescent Adult aerosol Aerosols Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Antibiotics Aztreonam Aztreonam - pharmacokinetics Aztreonam - therapeutic use Bacterial Load Care and treatment Child Chronic Disease Chronic infection Clinical trials Colonization Cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - physiopathology Drug Administration Schedule Drug Dosage Calculations Drugs Fibrosis Health aspects Humans Inhalation inhaled antibiotics Lung - drug effects Lung - microbiology Lung - physiopathology Lung diseases Mucus Nebulizers and Vaporizers Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - physiology Pseudomonas Infections - complications Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology Pseudomonas Infections - physiopathology Randomized Controlled Trials as Topic Respiratory tract Respiratory tract diseases Treatment Outcome
ISSN:	1478-7210, 1744-8336, 1744-8336
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!